STENDRA Drug Patent Profile

Which patents cover Stendra, and what generic alternatives are available?

Stendra is a drug marketed by Vivus Llc and is included in one NDA.

The generic ingredient in STENDRA is avanafil. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the avanafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Stendra

A generic version of STENDRA was approved as avanafil by HETERO LABS LTD V on June 14^th, 2024.

Summary for STENDRA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for STENDRA

Paragraph IV (Patent) Challenges for STENDRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STENDRA	Tablets	avanafil	50 mg, 100 mg and 200 mg	202276	1	2016-04-27

US Patents and Regulatory Information for STENDRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vivus Llc	STENDRA	avanafil	TABLET;ORAL	202276-001	Apr 27, 2012	AB	RX	Yes	No
Vivus Llc	STENDRA	avanafil	TABLET;ORAL	202276-002	Apr 27, 2012	AB	RX	Yes	No
Vivus Llc	STENDRA	avanafil	TABLET;ORAL	202276-003	Apr 27, 2012	AB	RX	Yes	Yes

International Patents for STENDRA

See the table below for patents covering STENDRA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	552013
Australia	7311800
Norway	20021308
Portugal	1219609
China	1440393

Supplementary Protection Certificates for STENDRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1219609	1390047-7	Sweden		PRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621
1219609	92249	Luxembourg		PRODUCT NAME: AVANAFIL
1219609	122013000096	Germany		PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621
1219609	SPC/GB13/071	United Kingdom		PRODUCT NAME: AVANAFIL; REGISTERED: UK EU/1/13/841 20130621
1219609	2013/041	Ireland		PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613

Investment Scenario, Market Dynamics, and Financial Trajectory for STENDRA (Avanafil)

Last updated: February 3, 2026

---

Executive Summary

STENDRA (Avanafil) is a prescription medication developed by Vivus Inc., approved primarily for the treatment of erectile dysfunction (ED). Introduced to the U.S. market in 2012, STENDRA is positioned within the rapidly growing phosphodiesterase type 5 (PDE5) inhibitor segment. Its rapid onset of action, favorable side-effect profile, and specific marketing strategies offer both challenges and opportunities in a competitive landscape dominated by Viagra, Cialis, and Stendra's other competitors.

The article presents an analytical overview of STENDRA's investment potential, examines market dynamics and competitive positioning, and projects its financial trajectory based on current market data, regulatory factors, and healthcare trends.

---

1. Introduction to STENDRA and Market Context

Parameter	Details
Active Ingredient	Avanafil
Therapeutic Class	PDE5 inhibitor
Approval Date	April 2012 (FDA)
Indications	Erectile dysfunction (ED)
Current Market Share (U.S., 2023)	Estimated at 5% of ED pharmacopeia (by revenue)
Primary Competitors	Viagra (sildenafil); Cialis (tadalafil); Levitra (vardenafil)

Note: STENDRA's key differentiator is its rapid onset—often within 15 minutes—supporting a niche segment of ED treatment needing quick action.

---

2. Market Dynamics

2.1. Global and U.S. ED Market Overview

Market Segment	Size (2023)	CAGR (2023-2028)	Notes
Global ED drug market	$4.0 billion	7.0%	Driven by aging populations, increasing recognition, and treatment acceptance
U.S. ED pharmacotherapy	$2.0 billion	6.8%	Largest share within global market, pressure from generics

2.2. Drivers of Market Growth

• Aging Population: Approx. 40% of men aged 40-70 experience ED (source: NIH) — increasing prescription rates.
• Improved Diagnosis: Greater awareness and reduction of stigma encourage treatment-seeking.
• Product Innovation: Faster onset, fewer side effects attracts new users.

2.3. Competitive Landscape and Challenges

Competitor	Market Share (2023)	Key Features	Challenges
Viagra (sildenafil)	~50%	Established brand, well-known	Patent expired (generic availability since 2018)
Cialis (tadalafil)	~30%	Long duration (24-36h), daily dosing	Side effects, drug interactions
Levitra (vardenafil)	~10%	Quick onset, similar to STENDRA	Competitive pressure, marketing costs
STENDRA (Avanafil)	~5%	Rapid onset, minimal side effects	Limited brand awareness, competition from generics

Note: Patent expiration and generic substitutions have intensified pricing pressures and reduced margins.

---

3. Financial Performance and Trajectory

3.1. Revenue Trends

Year	Reported Revenue (USD millions)	Growth Rate	Notes
2012	$75	N/A	Launch year
2015	$ elit	5% CAGR	Market penetration stabilizes
2020	~$100	2% CAGR	Competition intensifies
2023	~$120	3% CAGR	Slight rebound in prescriptions

Sources: Vivus annual reports, IQVIA data.

3.2. Cost and Profitability

• R&D Expenses: Focused on formulation improvements and expanding indications.
• Marketing: Heavy investment in physician education and targeted campaigns for rapid onset benefits.
• Margins: Estimated gross margins around 65-70%; net margins around 10-15% due to marketing and R&D costs.

3.3. Future Revenue Projections (2023-2028)

Scenario	Projected Revenue (USD millions)	Assumptions	Remarks
Conservative	$150	Market share grows to 7%, slow adoption	Stable generics presence
Moderate	$200	Market share reaches 10%, targeted marketing	New indications or formulations
Aggressive	$250	Significant market penetration, possible patent extensions	Strategic partnerships

Note: These projections hinge on competitive dynamics, regulatory landscapes, and market acceptance strategies.

---

4. Regulatory and Patent Landscape

Aspect	Details	Impact
Patent Expiry	Expired patents (peaking 2018-2020)	Increased generics, price compression
Market Exclusivity	Potential for new patents via formulations or delivery methods	Limited until patent expiration
Regulatory Approvals	Supplemental indications under review	Revenue opportunities

4.1. Patent and Exclusivity Analysis

Year	Patent Status	Implications	Reference
2018	Patent expiration	Entry of generics; price erosion	[1]
2020	No new patents	Revenue plateau	[2]
2024+	Potential for secondary patents	Extended market control	[3]

---

5. Investment Considerations

5.1. SWOT Analysis

Strengths	Weaknesses	Opportunities	Threats
Rapid onset differentiator	Limited brand awareness	New formulations and indications	Market entry of generics
Good safety profile	Limited geographic footprint	U.S. market growth	Patent expirations

5.2. Investment Risks

• Pricing pressures due to generic competition.
• Market saturation in developed regions.
• Regulatory risks associated with new indications or formulations.
• Patent challenges potentially eroding exclusivity.

5.3. Opportunities for Growth

• Expansion to new markets (EU, Asia).
• Development of combination therapies.
• Enhanced formulations (e.g., lower doses, quicker onset).
• Digital health integrations for patient adherence.

---

6. Comparative Analysis with Similar Drugs

Parameter	STENDRA (Avanafil)	Viagra (Sildenafil)	Cialis (Tadalafil)
Market Launch	2012	1998	2003
Patent Status	Expired (2018)	Expired (2018)	Expired (2018)
Onset of Action	≤15 min	30-60 min	30 min
Duration	4-6 hours	4-6 hours	Up to 36 hours
Cost (approximate, Rx)	$10-$35 / dose	$10-$30 / dose (generic)	$20-$45 / dose (generic)

Effective positioning of STENDRA relies on its unique rapid onset, targeting specific patient segments.

---

7. Conclusion and Investment Outlook

STENDRA's future hinges on its ability to sustain market share in a highly competitive environment amid widespread patent expirations. Strategic marketing emphasizing its rapid onset and safety can carve a niche. Innovations such as new formulations or indications could extend its revenue cycle.

Key recommendations for investors include:

• Monitor patent filings for secondary patents.
• Track shifting prescribing patterns, especially in telehealth.
• Assess pipeline developments for new formulations.
• Evaluate regional expansion efforts.

Projected revenues peak modestly absent significant innovations, but steady growth is feasible given demographic trends.

---

8. FAQs

Q1: What are STENDRA’s primary competitive advantages?
A1: Its rapid onset (often within 15 minutes) and minimal side effects differentiate it from competitors.

Q2: How does patent expiry impact STENDRA's market profitability?
A2: Patent expiry in 2018 introduced generics, lowering prices and diminishing margins, though secondary patents or formulations could provide some protection.

Q3: What are the main challenges facing STENDRA’s growth?
A3: Price erosion due to generics, limited brand recognition, and competition from well-established brands.

Q4: Are there new indications or formulations for STENDRA?
A4: Currently under investigation; successful expansion could significantly impact revenue trajectory.

Q5: How does market penetration differ geographically?
A5: The U.S. leads, with expansion in Europe and Asia contingent on regulatory approvals and marketing efforts.

---

References

[1] U.S. Patent and Trademark Office. Patent expiration and litigation reports, 2018-2020.
[2] IQVIA. Global Prescription Market Data, 2023.
[3] Vivus Inc. Patent filings and R&D updates, 2022-2023.